Related Experiment Video

Updated: Apr 16, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Implications of miRNAs in Colorectal Cancer Chemoresistance

Jingfang Ju1

  • 1Translational Research Laboratory, Department of Pathology, Stony Brook University.

International Drug Discovery
|March 10, 2015
PubMed

Insights

MicroRNAs (miRNAs) are key regulators in diseases like cancer. This review explores how miRNAs mediate chemoresistance to 5-fluorouracil in colorectal cancer, offering new therapeutic strategies.

Area of Science:

  • Biomedical Sciences
  • Molecular Biology
  • Oncology

Background:

  • MicroRNAs (miRNAs) are crucial non-coding RNA molecules with significant roles in various human diseases, including cancer.
  • Alterations in miRNA expression profoundly impact gene regulation and cellular pathways.
  • Chemoresistance to 5-fluorouracil (5-FU) remains a major challenge in treating advanced colorectal cancer.

Purpose of the Study:

  • To review recent advancements in understanding miRNA-mediated chemoresistance mechanisms in colorectal cancer.
  • To focus on the role of miRNAs in resistance to 5-FU chemotherapy.
  • To explore the involvement of cancer stem cells in miRNA-mediated chemoresistance.

Main Methods:

  • Literature review of recent research on microRNAs and colorectal cancer chemoresistance.
  • Analysis of studies investigating miRNA roles in 5-FU resistance.
  • Examination of data concerning cancer stem cells and miRNA-mediated resistance.

Main Results:

  • MicroRNAs play a significant role in the development of chemoresistance in colorectal cancer.
  • Specific miRNAs can either promote or inhibit resistance to 5-FU chemotherapy.
  • Cancer stem cells exhibit unique miRNA expression profiles contributing to therapeutic resistance.

Conclusions:

  • Understanding miRNA-mediated resistance mechanisms is vital for improving colorectal cancer treatment.
  • Targeting specific miRNAs could overcome chemoresistance and enhance therapeutic efficacy.
  • MiRNA-based strategies hold promise for developing novel anti-cancer therapies for colorectal cancer.

More Related Videos

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

11.6K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.9K
MicroRNAs01:22

MicroRNAs

12.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K